Jeffrey Yu, who serves as the Chief Medical Officer and a director at OneMedNet Corp (NASDAQ: ONMD), has executed a significant acquisition of company equity. On June 23, 2026, Mr. Yu purchased 158,730 shares of common stock at a price of $0.63 per share, totaling approximately $99,999. This transaction was structured as part of a subscription agreement for a $100,000 investment in the issuer. The purchase price aligns with recent market activity, as the stock has been trading near the $0.60 level. According to InvestingPro data, the shares have declined approximately 55% over the past six months. OneMedNet currently maintains a market capitalization of $32.66 million. Financial metrics indicate that the company has reported revenue growth of 148%, yet it remains unprofitable with an earnings per share (EPS) of -$0.07. Data highlights from InvestingPro note that the company is rapidly consuming cash, a detail included among 12 additional insights available to subscribers.
Following the completion of this acquisition, Mr. Yu’s direct ownership of OneMedNet Corp common stock stands at 8,780,410 shares. In addition to these direct holdings, a trust established for his children holds 1,311,970 shares indirectly. Mr. Yu has formally disclaimed beneficial ownership of these indirectly held shares, clarifying that they are managed by an independent trustee over which he exercises no investment control. This separation underscores the distinct nature of his direct equity position relative to the family trust arrangements.
Recent operational developments at OneMedNet Corporation highlight substantial financial shifts. The company reported a 329% year-over-year increase in revenue, reaching $1.25 million in 2025, a marked increase from $292,000 in 2024. The fourth-quarter revenue specifically totaled $890,000. Concurrently, the company successfully reduced its liabilities by 74%, decreasing the total from $19.7 million to $5.1 million. Forward-looking indicators suggest strong near-term activity, with OneMedNet securing over $3 million in bookings for 2026. This figure surpasses the total bookings recorded for 2025, and these bookings are projected to be recognized as revenue by the conclusion of the third quarter of 2026.
Market data for ONMD reflects recent trading activity. The stock closed at $0.60, representing a $0.0412 increase or a 7.37% gain on June 23. Pre-market trading on June 9 showed the stock at $0.6411, up $0.0411 or 6.85%. The company is currently navigating regulatory requirements, having received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the $1.00 minimum bid price requirement for continued listing. OneMedNet has been granted 180 days to regain compliance with this standard. Additionally, the company has initiated a collaboration with Inka Health to gain access to its iRWD platform, which supports oncology data. This partnership is designed to facilitate the development of Onco-Innovations’ cancer treatment technology.
Key Points:
- Executive Insider Buying: Jeffrey Yu, CMO and director, acquired $99,999 in shares, signaling internal engagement with the company's equity value at current market levels.
- Revenue Expansion and Liability Reduction: OneMedNet reported a 329% year-over-year revenue increase to $1.25 million in 2025 and reduced liabilities by 74% to $5.1 million, indicating operational scaling and financial restructuring.
- Regulatory Compliance and Strategic Partnerships: The company faces a 180-day deadline to meet Nasdaq's $1.00 minimum bid price requirement while simultaneously advancing oncology technology through a collaboration with Inka Health.
Risks and Uncertainties:
- Nasdaq Listing Compliance: The notice regarding the $1.00 minimum bid price requirement poses a significant risk to the company's continued listing status, requiring immediate action within the 180-day window to avoid potential delisting.
- Cash Burn and Profitability: Despite revenue growth, the company remains unprofitable with an EPS of -$0.07 and is noted to be quickly burning through cash, which may impact its ability to sustain operations without additional capital raises.
- Revenue Recognition Timing: The $3 million in bookings for 2026 are expected to be recognized as revenue by the end of the third quarter of 2026, introducing uncertainty regarding the timing and realization of these financial benefits.